Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

Zacks09-06

Shares of Hoth Therapeutics HOTH surged 81.4% on Sept. 5, after the company announced positive data from the treatment of the first patient with its lead candidate, HT-001, who was experiencing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465612908?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2zpBip7dfc108UBup7QGiw--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/28fc1568786cf7bd1a1b4ba4d8d32823","is_english":true,"pubTime":"2024-09-06 22:43","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2465612908","market":"us","top_or_hot":-1,"title":"Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient","media":"Zacks","content":"<div>\n<p>Shares of Hoth Therapeutics HOTH surged 81.4% on Sept. 5, after the company announced positive data from the treatment of the first patient with its lead candidate, HT-001, who was experiencing ...</p>\n\n<a href=\"https://finance.yahoo.com/news/hoth-stock-lead-drug-heals-144300280.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-06 22:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/hoth-stock-lead-drug-heals-144300280.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Hoth Therapeutics HOTH surged 81.4% on Sept. 5, after the company announced positive data from the treatment of the first patient with its lead candidate, HT-001, who was experiencing ...</p>\n\n<a href=\"https://finance.yahoo.com/news/hoth-stock-lead-drug-heals-144300280.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRYS","symbol_name":"Krystal Biotech Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/hoth-stock-lead-drug-heals-144300280.html","article_id":"2465612908","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2zpBip7dfc108UBup7QGiw--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/28fc1568786cf7bd1a1b4ba4d8d32823"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465612908","pubTimestamp":1725633780,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares ofHoth Therapeutics HOTH surged 81.4% on Sept. 5, after the company announced positive data from the treatment of the first patient with its lead candidate, HT-001, who was experiencing papulopustular eruptions . Notably, PPEs are a common and debilitating side effect of EGFR inhibitor  therapy in cancer patients.Hoth’s HT-001 Demonstrates Superior Efficacy in PPEs Treatment. In this groundbreaking case, the 59-year-old female patient undergoing treatment for metastatic breast cancer witnessed significant improvement in symptoms just one week after receiving the novel therapeutic. Based on the rapid healing of lesions and relief of discomfort, the patient discontinued treatment after just one week.Importantly, no new lesions appeared over the next three weeks, underscoring HT-001's potential as a safe and effective treatment for EGFRI-related PPEs. Such results mark a significant milestone in addressing a serious unmet medical need experienced by cancer patients receiving EGFRI ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRYS":"Krystal Biotech Inc.","BK4139":"生物科技","FULC":"Fulcrum Therapeutics","BK4588":"碎股","BK4585":"ETF&股票定投概念","HOTH":"Hoth Therapeutics","BK4007":"制药","BK4534":"瑞士信贷持仓","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4121":"生命科学工具和服务","ILMN":"Illumina"},"translate_title":"霍斯储备作为治疗癌症患者皮肤毒性的主要药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FULC":1,"HOTH":1,"ILMN":1,"KRYS":1},"content_text":"Shares of Hoth Therapeutics HOTH surged 81.4% on Sept. 5, after the company announced positive data from the treatment of the first patient with its lead candidate, HT-001, who was experiencing papulopustular eruptions (PPEs). Notably, PPEs are a common and debilitating side effect of EGFR inhibitor (EGFRI) therapy in cancer patients.\nHoth’s HT-001 Demonstrates Superior Efficacy in PPEs Treatment\nIn this groundbreaking case, the 59-year-old female patient undergoing treatment for metastatic breast cancer witnessed significant improvement in symptoms just one week after receiving the novel therapeutic. Based on the rapid healing of lesions and relief of discomfort, the patient discontinued treatment after just one week.\nImportantly, no new lesions appeared over the next three weeks, underscoring HT-001's potential as a safe and effective treatment for EGFRI-related PPEs. Such results mark a significant milestone in addressing a serious unmet medical need experienced by cancer patients receiving EGFRI therapy. If successfully developed, the candidate could greatly improve the quality of life for cancer patients suffering from EGFRI-induced skin toxicities.\nYear to date, shares of HOTH have lost 12.5% compared with the industry’s 0.9% decline.\nImage Source: Zacks Investment Research\nEGFRIs, commonly used to treat various epithelial cancers, often cause skin side effects in the form of PPEs like acneiform rashes, affecting up to 90% of patients. These side effects, causing pruritus (itching) and burning, can be severe enough to disrupt or stop cancer treatments. HT-001 presents a new solution for managing these skin toxicities, providing quick symptom relief without interrupting the patient's ongoing cancer therapy.\nHOTH’s Future Development Plans for HT-001 to Treat EGFRI-Induced PPEs\nIn a separate press release, Hoth announced that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its first-in-human mid-stage study of topical HT-001 to treat EGFRI-induced skin toxicities.\nPer management, the ongoing phase IIa dose-ranging study will evaluate theefficacy, safety and tolerability of the candidate to treat the above indication.\nHoth’s Developmental Pipeline Beyond HT-001\nApart from the lead candidate HT-001, which is being developed for EGFRI-induced skin toxicities, Hoth is developing several other next-generation therapies for different unmet medical needs. One such investigational candidate is BioLexa, which is currently being developed in a separate early-stage study for the treatment of atopic dermatitis.\n\nHoth Therapeutics, Inc. Price and Consensus\n\nHoth Therapeutics, Inc. price-consensus-chart | Hoth Therapeutics, Inc. Quote\n\nZacks Rank & Other Stocks to Consider\nHoth currently carries a Zacks Rank #2 (Buy).\nSome other top-ranked stocks in the biotech sector are Illumina, Inc. ILMN, Krystal Biotech, Inc. KRYS and Fulcrum Therapeutics, Inc. FULC, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 6.8%.\nILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.\nIn the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have increased from $1.98 to $2.37. Earnings per share estimates for 2025 have improved from $4.33 to $7.59. Year to date, shares of KRYS have risen 50%.\nKRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.\nIn the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 27.9%.\nFULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nIllumina, Inc. (ILMN) : Free Stock Analysis Report\nKrystal Biotech, Inc. (KRYS) : Free Stock Analysis Report\nHoth Therapeutics, Inc. (HOTH) : Free Stock Analysis Report\nFulcrum Therapeutics, Inc. (FULC) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465612908"}